Despite the overall strength of the economy, 2024 has been a challenging year for the biotech industry. The rising cost of borrowing — especially before the Fed cut its interest rate for the first time in several years in September — coupled with the changing landscape for the health care sector has dampened the outlook for many companies. As a result, the iShares Biotechnology ETF has become the benchmark Nasdaq: EP It was very volatile but ended up 1.2% in the year ending January 17, 2025.
Biotechnology is a high-risk, high-reward field, with a large number of startups in the industry working to raise enough funding to keep operations running long enough to hopefully see an important new product reach the market. When things come together, it can be a huge boon for investors — approvals of blockbuster drugs and even positive clinical trial results can sometimes send stocks rising by hundreds of percentage points.
As always, trying to time the market is likely to be futile. But investors are looking for an opportunity to buy the dip in two popular companies – Avadel Pharmaceuticals plc Nasdaq: AVDL Sana Biotechnology Company. Nasdaq: SANA– He might get lucky in early 2025. Meanwhile, a third company with a recent history of going up, ADMA Biologics Inc. Nasdaq: ADMAcould still represent an opportunity for future growth.
Avadel Pharmaceuticals: Disappointing guidance presents a buying opportunity
Avadel Pharmaceuticals stock forecast today
$21.00
He buys
Based on 7 analyst ratings
| High expectations | $30.00 |
|---|---|
| Average expectations | $21.00 |
| Low expectations | $13.00 |
Avadel Pharmaceuticals stock forecast details
Avadel is best known for Lumryz, a unique treatment for treating excessive daytime sleepiness in adults with narcolepsy. Despite the fact that the company reported $50 million in net product revenue for the fourth quarter, an increase of more than 150% year over year, shares fell early in January with the news that the company Avadel has set guidance for net product revenue In the range of $240-260 million, which is lower than analysts’ expectations.
Lumryz faces the hurdle of patient attrition, but Avadil is proactively working to boost uptake in patients switching from other medications. The company is also enrolling patients in a phase 3 trial to evaluate some other aspects of the effectiveness and safety of Lumryz. Fortunately for investors, Avadel has some leeway to address fundamental issues: The company has more than $70 million in cash on hand and is likely to generate positive cash flow between $20 million and $40 million this year.
Investors who are comfortable with Avadel’s long-term risk may find that now may be a good time to invest — as of January 17, 2025, shares are down more than 48% in the past year.
SANA Biotechnology: The possibility of launching new methods to treat type 1 diabetes
SANA biotechnology stock forecast today
$14.25
Moderate purchase
Based on 5 analyst ratings
| High expectations | $16.00 |
|---|---|
| Average expectations | $14.25 |
| Low expectations | $11.00 |
Details of SANA’s biotechnology stock forecast
SANA is a clinical-stage biotech company for gene and cell therapy and its stock has fallen 48.5% in the year ended January 17, 2025. However, what may set this company apart from a group of biotech companies with similarly penny stocks is that it is being studied. Investigational allogeneic cell therapy in type 1 diabetes.
a lot It was revealed in early January Data from her study involved an allogeneic transplant — transplanting healthy donor cells into the body of a patient seeking treatment. Specifically, the study showed “survival of an allogeneic transplant without any immunosuppression or immune defense,” according to Sana, and this is likely the first study of its kind. This could open up new ways to treat type 1 diabetes and many other diseases as well, if the company can replicate safe cell transplants without immunosuppression.
As soon as the news was announced, the value of SANA shares doubled. They remain up about 65% in the past month as of January 17, and four out of five analysts continue to view the stock as a buy with more than 350% upside potential based on the consensus price target of $14.25.
ADMA Biologics: The Fast Track to Growth
ADMA Biologics stock forecast today
$21.25
He buys
Based on 4 analyst ratings
| High expectations | $26.00 |
|---|---|
| Average expectations | $21.25 |
| Low expectations | $14.00 |
ADMA Biologics stock forecast details
ADMA had a Big year in 2024; As it moved to increase the marketing of some of its products, revenues and net income grew significantly. In the third quarter of 2024, revenue rose 78% year over year to nearly $120 million, while net income increased an incredible 1,300% to just under $36 million.
ADMA’s gross and net growth should help strengthen its balance sheet, as the company said it expects to reach a leverage-neutral net position in the fourth quarter of 2024. It also increased its full-year 2025 revenue guidance to more than $485, from More than $415 million, with full-year 2026 revenues expected to exceed $600 million. Furthermore, ADMA believes it will achieve total annual revenues of $1 billion before 2030, indicating that the pace of growth may continue.
Although ADMA shares are up 228% in the past year, analysts believe there is still plenty of upside potential left.
Before you consider Avadel Pharmaceuticals, you’ll need to hear this.
MarketBeat tracks the highest-rated and best-performing research analysts on Wall Street and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches up… and Avadel Pharmaceuticals was not on the list.
While Avadel Pharmaceuticals currently has a “buy” rating among analysts, top-rated analysts believe these 5 stocks are better buys.
View the five stocks here
Growth stocks offer a lot of bang for your buck, and we have upcoming superstars you should strongly consider for your portfolio.
